Overview of the Development and Use of Akt Inhibitors in Prostate Cancer.

J Clin Med · 2021 · PMC8745410 · PMID 35011901

Europe PMC DOI

hedged sentence

0.1700

closest p · 3.4× alpha

0.1700

boldest claim

The sentences

showed a trendp = 0.17not close (p > 0.1)

Ipatasertib 400 mg showed a trend to increased radiological PFS (median 8.18 vs. 6.37 months; HR = 0.75; p = 0.17) and increased OS (median 18.92 months vs. 15.64 months; HR = 0.72; p = 0.22), compared to placebo.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.